A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001487-37

A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy from Age-related Macular Degeneration

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the safety of the Brimo PS DDS Applicator System (200 μg and 400 μg brimonidine tartrate) in patients with geographic atrophy (GA) from age-related macular degeneration (AMD) To evaluate the effects of the Brimo PS DDS Applicator System (200 μg and 400 μg brimonidine tartrate) on retinal structure in patients with GA from AMD To evaluate the effects of the Brimo PS DDS Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with GA from AMD


Critère d'inclusion

  • Geographic Atrophy from Age-related Macular Degeneration